AR056816A1 - Composicion con ácido docosapentenoico - Google Patents

Composicion con ácido docosapentenoico

Info

Publication number
AR056816A1
AR056816A1 ARP060105069A ARP060105069A AR056816A1 AR 056816 A1 AR056816 A1 AR 056816A1 AR P060105069 A ARP060105069 A AR P060105069A AR P060105069 A ARP060105069 A AR P060105069A AR 056816 A1 AR056816 A1 AR 056816A1
Authority
AR
Argentina
Prior art keywords
composition
acid
docosapentenoic acid
docosapentenoic
subject
Prior art date
Application number
ARP060105069A
Other languages
English (en)
Inventor
Linette Eustachia M Willemsen
Tol Eric Alexander F Van
Christopher Beerman
Original Assignee
Nutricia Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutricia Nv filed Critical Nutricia Nv
Publication of AR056816A1 publication Critical patent/AR056816A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Método para estimular la integridad de barrera en un sujeto, que comprende administrarle a un sujeto una composicion que comprende ácido docosapentenoico (22:5 n3; DPA). La presente también se relaciona con una composicon que comprende DPA y ácido eicosapentenoico (EPA).
ARP060105069A 2005-11-17 2006-11-17 Composicion con ácido docosapentenoico AR056816A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2005/050044 WO2007058523A1 (en) 2005-11-17 2005-11-17 Composition with docosapentaenoic acid

Publications (1)

Publication Number Publication Date
AR056816A1 true AR056816A1 (es) 2007-10-24

Family

ID=36570308

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105069A AR056816A1 (es) 2005-11-17 2006-11-17 Composicion con ácido docosapentenoico

Country Status (5)

Country Link
US (1) US20090054329A1 (es)
EP (1) EP1948156A2 (es)
CN (1) CN101360490A (es)
AR (1) AR056816A1 (es)
WO (2) WO2007058523A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2445401T3 (es) * 2007-06-26 2014-03-03 N.V. Nutricia Aumentar la memoria en sujetos con mini examen del estado mental de 24-26
WO2009002145A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving function of brain functioning
WO2009002146A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Supporting activities of daily living
WO2009002148A1 (en) 2007-06-27 2008-12-31 N.V. Nutricia Food composition for prodromal dementia patients
US9107439B2 (en) 2007-10-09 2015-08-18 Enzymotec Ltd. Lipid compositions for the treatment of gastro-intestinal disorders and the promotion of intestinal development and maturation
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
US8282965B2 (en) 2007-12-20 2012-10-09 N.V. Nutricia Liquid nucleotides/nucleosides-containing product
ES2862336T3 (es) 2008-09-02 2021-10-07 Amarin Pharmaceuticals Ie Ltd Composición farmacéutica que comprende ácido eicosapentaenoico y ácido nicotínico y métodos de uso de la misma
ES2345241B1 (es) 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
NZ771180A (en) 2009-04-29 2022-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
DK3278665T3 (da) 2009-04-29 2020-11-30 Amarin Pharmaceuticals Ie Ltd Stabil farmaceutisk sammensætning og fremgangsmåder til anvendelse deraf
CN102625847A (zh) 2009-06-15 2012-08-01 阿马里纳制药公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
MX2012003555A (es) 2009-09-23 2012-07-03 Amarin Corp Plc Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
AU2011336856A1 (en) 2010-11-29 2013-07-04 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
CA2822219C (en) 2010-12-31 2020-12-29 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
CA2842672A1 (en) 2011-07-22 2013-01-31 Abbott Laboratories Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013103958A1 (en) 2012-01-06 2013-07-11 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
CA2916208A1 (en) 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
HUE053111T2 (hu) 2012-06-29 2021-06-28 Amarin Pharmaceuticals Ie Ltd Módszerek kardiovaszkuláris események veszélyének csökkentésére sztatin terápiával kezelt alanyban eikozapentaénsav-etilészter alkalmazásával
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
KR20210059779A (ko) 2012-12-06 2021-05-25 마티나스 바이오파마, 인코포레이티드 오메가-3 펜타엔산 조성물 및 사용 방법
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
EP2968246A4 (en) * 2013-03-13 2016-08-03 Matinas Biopharma Inc OMEGA 3 PENTANOIC ACID COMPOSITIONS AND METHODS OF USE
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
EP3820307A1 (en) * 2018-07-12 2021-05-19 N.V. Nutricia Nutritional composition for improving intestinal barrier integrity, preparation of the composition and method of treatment
MX2021002207A (es) * 2018-08-29 2021-07-15 Dsm Ip Assets Bv Formulaciones para mejorar la salud intestinal.
FI4056176T3 (fi) 2018-09-24 2024-05-30 Amarin Pharmaceuticals Ie Ltd Menetelmät kardiovaskulaaristen tapahtumien riskin pienentämiseksi tutkittavassa
EP4326244A1 (en) 2021-04-21 2024-02-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260067A (en) * 1988-11-16 1993-11-09 Xu Zheng Cytotropic heterogeneous molecular lipids (CHML) and process for preparing the same
SE9101642D0 (sv) * 1991-05-30 1991-05-30 Kabi Pharmacia Ab Phospholipids
JP4394174B2 (ja) * 1995-09-06 2010-01-06 イーエヌ大塚製薬株式会社 炎症性腸疾患治療剤
DK1166652T4 (en) * 1999-03-04 2016-10-24 Suntory Holdings Ltd The use of material containing 4, 7, 10, 13, 16-docosapentaenoic acid
CN1166368C (zh) * 2003-02-26 2004-09-15 刘威 海狗油脂肪乳注射液、其制备方法及其在制备静脉注射剂中的应用
US8252769B2 (en) * 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
EP1656839A1 (en) * 2004-11-11 2006-05-17 N.V. Nutricia Nutrition containing lipid blend

Also Published As

Publication number Publication date
US20090054329A1 (en) 2009-02-26
WO2007058523A1 (en) 2007-05-24
CN101360490A (zh) 2009-02-04
WO2007058538A3 (en) 2008-06-12
WO2007058538A2 (en) 2007-05-24
EP1948156A2 (en) 2008-07-30

Similar Documents

Publication Publication Date Title
AR056816A1 (es) Composicion con ácido docosapentenoico
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
EA201001529A1 (ru) Способ и композиция для лечения mif-опосредованных расстройств
TW200719913A (en) Anti-madcam antibody compositions
AR057614A1 (es) Composiciones y metodos para producir moleculas de union con antigeno hibridas y usos de las mismas
CR11418A (es) Trans-clomifeno para el sindrome metabolico
UY31789A1 (es) Composiciones de insulina de super rápida actuación
GT200900035A (es) Anticuerpo especifico prlr y sus usos
EA200802319A1 (ru) Способ и устройство для ремонта элементов конструкции
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
EA200701029A1 (ru) Новая композиция для облегчения человеческих родов
WO2007133721A3 (en) Food compositions and methods of treating periodontal disease
ECSP077387A (es) Composiciones que contienen piperacilina, tazobactam y un ácido aminocarboxílico en un diluyente de lactato de sodio
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
EA200701172A1 (ru) 2-алкокси-3,4,5-тригидроксиалкиламиды, их получение, композиции, их содержащие, и применение
WO2008008348A3 (en) Method and compositions for treating stroke with fever
WO2007079312A3 (en) Compositions and methods for treating actin-mediated medical conditions
NO20070351L (no) Materialer og fremgangsmater for forbedring av skalldyrhelse, -immunitet og -vekst
AR074302A1 (es) Trans-clomifeno para el sindrome metabolico y la diabetes mellitus tipo 2.. metodo
WO2005077356A3 (en) Glycine and/or for use in cartilage affecting conditions
AR062248A1 (es) Composiciones y metodos para tratar artritis reumatoidea
MX2008009830A (es) Efecto del inhibidor bst2.
GT200800297A (es) Formulaciones galenicas de alisquireno e hidroclorotiazida
WO2008059041A3 (en) Complementation of factor xi deficiency by factor v mutants
AR057247A1 (es) Composiciones que comprenden por lo menos una enzima para reducir el estres inmunologico

Legal Events

Date Code Title Description
FB Suspension of granting procedure